Kirin Holdings Co. Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Yoshinori Isozaki
- Full Time Employees
- 31,144
- Sector
- Consumer non-durables
- Industry
- Beverages: alcoholic
- Address
- Nakano Central Park South Tokyo TY Japan 164-0001
- IPO Date
- May 16, 1949
- Website
- kirinholdings.co.jp
- Similar Companies
- Business
- Kirin Holdings Company, Limited, a holding company overseeing operations in food and beverages, pharmaceuticals, and health science domains, develops group-wide management strategies and supervises their execution. Incorporated on February 23, 1907, and headquartered at Nakano Central Park South, 10-2 Nakano 4-chome, Nakano-ku, Tokyo 164-0001, Japan, the company traces its origins to Japan Brewery established in 1885 and focuses on fermentation and biotechnology technologies across its businesses. It operates primarily in Japan, with significant presence in Asia-Pacific regions including the Philippines via a 48% stake in San Miguel Brewery, Australia through Blackmores, Oceania, Southeast Asia, and North America; consolidated revenue reaches 2,338,385 million yen for the fiscal year ended December 31, 2024, with 31,934 employees. Kirin Holdings offers a diverse portfolio of alcoholic beverages including Kirin Lager Beer, Ichiban Shibori, craft beers, hard liquor, and wine; non-alcoholic beverages such as tea, fruit juices, and soft drinks; food products; and pharmaceuticals encompassing raw materials, plant genetics, bioengineering, and health science offerings through subsidiaries like FANCL for skincare and supplements and Kyowa Kirin for biopharmaceuticals. In recent developments, Kirin Holdings completes a tender offer in September 2024 to acquire additional shares in FANCL Corporation, increasing ownership to 75.24% and designating it a consolidated subsidiary effective September 19, 2024, with plans for full ownership via squeeze-out procedures to bolster its health science domain and accelerate synergies with Blackmores toward becoming one of Asia-Pacific's largest health science companies. The company pursues its Kirin Group Vision 2027 (KV2027) emphasizing customer-centric marketing, R&D in fermentation and biotechnology, digital transformation, and sustainability goals like carbon neutrality by 2030; in October 2025, it initiates the sale of Four Roses whiskey brand for approximately $1 billion to reallocate capital toward health sciences.
Company News
Kirin (KNBWY) is an Incredible Growth Stock: 3 Reasons Why
Are Investors Undervaluing Kirin (KNBWY) Right Now?
Arcadia Biosciences (NASDAQ:RKDA) and Kirin (OTCMKTS:KNBWY) Financial Survey
The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
Kyowa Kirin stops development of skin condition treatment
3 Reasons Growth Investors Will Love Kirin (KNBWY)
Kirin (KNBWY) Upgraded to Buy: What Does It Mean for the Stock?
Is Kirin (KNBWY) Stock Undervalued Right Now?
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
Should Value Investors Buy Kirin (KNBWY) Stock?
Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia